John Nicols Net Worth

The estimated Net Worth of John J Nicols is at least 16.4 百万$ dollars as of 17 April 2023. Mr. Nicols owns over 71,428 units of Codexis stock worth over 2,237,724$ and over the last 21 years he sold CDXS stock worth over 10,728,678$. In addition, he makes 3,408,030$ as President、 Chief Executive Officer、 Director at Codexis.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Nicols CDXS stock SEC Form 4 insiders trading

John has made over 38 trades of the Codexis stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 71,428 units of CDXS stock worth 140,713$ on 17 April 2023.

The largest trade he's ever made was selling 95,443 units of Codexis stock on 20 April 2012 worth over 6,082,582$. On average, John trades about 23,676 units every 98 days since 2004. As of 17 April 2023 he still owns at least 819,679 units of Codexis stock.

You can see the complete history of Mr. Nicols stock trades at the bottom of the page.

John Nicols biography

John J. Nicols serves as President, Chief Executive Officer, Director of Codexis, Inc. Mr. Nicols brings to our board of directors his knowledge of Codexis as its President and Chief Executive Officer and his extensive prior management experience in the chemicals industry. Prior to that time, Mr. Nicols served in various capacities at Albemarle Corporation, a public company focused on the development, manufacture and marketing of highly engineered specialty chemicals, since he joined that company in 1990. Mr. Nicols most recently served as its Senior Vice President, Strategic Development and Catalysts, from March 2012 to June 2012. Mr. Nicols previously served as its Vice President, Catalysts from January 2007 to February 2012, its Vice President, Fine Chemistry from June 2002 to December 2006, its Division Vice President, Global Flame Retardants business from February 1999 through June 2002 and its Asia Pacific Business Director for the Bromine Chemicals business, based in Tokyo, Japan, from 1995 to 1998. Prior to his time with Albemarle Corporation, Mr. Nicols worked for three years in manufacturing and research and development for Hercules, Inc. Mr. Nicols has served on the board of directors of California Life Sciences Association (formerly BayBio), a non-profit organization, since January 2014. In addition, Mr. Nicols has served on the board of directors of Solve ME/CFS Initiative, a non-profit organization, since January 2015, and currently serves as chairperson and on the executive and nominating committees of that organization. Mr. Nicols received a B.S. in Chemical Engineering from the Polytechnic Institute of New York University and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.

What is the salary of John Nicols?

As the President、 Chief Executive Officer、 Director of Codexis, the total compensation of John Nicols at Codexis is 3,408,030$. There are no executives at Codexis getting paid more.

How old is John Nicols?

John Nicols is 56, he's been the President、 Chief Executive Officer、 Director of Codexis since 2012. There are 10 older and 1 younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.

What's John Nicols's mailing address?

John's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Codexis

Over the last 15 years, insiders at Codexis have traded over 34,923,852$ worth of Codexis stock and bought 399,963 units worth 1,488,111$ . The most active insiders traders include Ventures Vii, Llc Vivo Vent...、Ventures Life Sciences 2000...、John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of 153,997$. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth 42,200$.

What does Codexis do?

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop

Complete history of Mr. Nicols stock trades at Codexis、Albemarle

Codexis executives and stock owners

Codexis executives and other stock owners filed with the SEC include:

• John Nicols,
  President, Chief Executive Officer, Director
• John J. Nicols,
  Pres, CEO & Director
• Ross Taylor Jr., M.B.A.,
  Sr. VP & CFO
• Ross Taylor,
  Chief Financial Officer, Senior Vice President
• Bernard Kelley,
  Independent Chairman of the Board
• Byron Dorgan,
  Independent Director
• Pam Cheng,
  Independent Director
• David Smith,
  Independent Director
• Patrick Yang,
  Independent Director
• Dennis Wolf,
  Independent Director
• Thomas Baruch,
  Independent Director
• Jennifer Aaker,
  Independent Director
• Karen Frechou-Armijo,
  Sr. VP & Head of HR
• Asli Aras Ph.D.,
  VP of Corp. Devel.
• Dr. Davinder Singh Brar,
  Special Advisor to the Board
• Prof. Gerhard N. Mayr,
  Special Advisor to the Board
• Robert Sato M.B.A., Ph.D.,
  Sr. VP of Pharmaceutical Devel., Quality & Regulatory
• Dr. Stefan Lutz Ph.D.,
  Sr. VP of Research
• Rob Wilson Ph.D.,
  Sr. VP & GM of Performance Enzymes
• Dr. Gjalt Huisman Ph.D.,
  Sr. VP of Strategic Devel. & GM of Biotherapeutics
• Dr. Karl A. Schoene Ph.D.,
  Sr. VP of Devel. & Operations
• Kathleen Sereda Glaub,
  Director
• Gordon Sangster,
  SVP & Chief Financial Officer
• James Lalonde,
  SVP, R&D
• Ventures Vii, Llc Vivo Vent...,
  
• Douglas T. Sheehy,
  SVP, Gen Counsel and Sec.
• Sriram Ryali,
  Chief Financial Officer
• Ventures Fund Vii, L.P.Vivo...,
  
• David D O'toole,
  SVP & Chief Financial Officer
• Alexander Karsner,
  Director
• Matthew Tobin,
  SVP, Research & Development
• David L. Anton,
  SVP, Research and Development
• Ventures Life Sciences 2000...,
  
• James R Sulat,
  Director
• Mun Yew Wong,
  Director
• Brazil Holding B.V. Shell,
  10% owner
• Bruce A Pasternack,
  Director
• Robert J Lawson,
  SVP and CFO
• Brian Paul Dowd,
  Interim CFO
• Inc Maxygen,
  10% owner
• Peter M Strumph,
  Interim President and CEO
• Joseph J. Sarret,
  CBO, President Pharmaceuticals
• Peter Seufer Wasserthal,
  SVP, Pharmaceuticals
• Enterprises Llc Royal Dutch...,
  
• Alan Shaw,
  President and CEO
• Enterprises Llc Equilon,
  10% owner
• Participacoes Ltda.Royal Du...,
  
• Sciences Investment Fund Pt...,
  
• Esther Martinborough,
  
• H Stewart Parker,
  
• Rahul Singhvi,
  
• Alison Moore,
  
• Margaret Nell Fitzgerald,
  See Remarks
• Stephen George Dilly,
  See Remarks
• Kevin Norrett,
  Chief Operating Officer